Cytosurge at a glance
The company, our values, our history.
Jump to: Company Values | Team | Cytosurge History
Cytosurge is a synthetic biology enabler. We are dedicated to fulfilling the unmet need for implementing complex genetic designs into gene-edited mammalian cell lines. We thereby bridge the manufacturing gap between the advances made in data driven genetic design tools and tangible applications of genetically engineered cells. The company applies a patented single cell bottom-up gene editing process and groundbreaking dynamic gene expression analysis capabilities to construct, evaluate, and debug complex synthetic mammalian cell lines. We are thereby effectively addressing a major pain point of current genetic engineering workflows in mammalian cell lines. Our initial focus lies in enhancing therapy manufacturing for future cures, with the ultimate goal to empower genetic engineers to concentrate on designing next-generation gene edited mammalian cell lines, confident that their visionary concepts can be realized.
Our Vision
Cytosurge unlocks novel cures by translating next-generation genetic designs into living cells. Cytosurge is the partner of choice for precision gene engineering cell line manufacturing. Cytosurge thereby enables next generation biologic production and cell and gene therapy treatments so people can live longer and healthier lives.
Our Mission
Cytosurge implements advanced genetically engineered cell lines that bring next-generation therapies to fruition. Cytosurge bridges the gap between genetic design tools and manufacturing of high precision gene engineered cell lines. A unique single-cell workflow and our dynamic gene expression analytics enable us to manufacture advanced gene engineered cell lines to empower next-generation treatments to benefit human well-being.
40+
Employees
150+
FluidFM publications
140+
Installations around the world
10+
Christmas parties
Our Values
Aim for top customer experience
Listening to our customers to understand their needs and problems is the source for our business drive. We aim to offer a great customer experience in all we do.
Innovate & evolve
We think outside the box and embrace innovation. We take responsibility in the things we do and are not afraid of doing mistakes. We evolve continuously.
Trust each other
We give each other the autonomy and freedom to be awesome at what we do. If a mistake happens, we don't blame, we help each other.
Execute fast
We are committed to fast execution. Having a ‘MVP’ mindset, we do less but faster and make it perfect in the long-term. Agile and lean.
Keep things simple
Adding complexity is easy, keeping things simple is difficult. We are dedicated to keep things simple to maintain agility and efficiency.
Think long-term
We keep track of our ultimate goals and assess if an action will support us in the long-term, balancing short- and long-term thinking.
Our History
2025 - 40+ Employees, 150+ FluidFM publications, 140+ Installations around the World
2025 - Leadership Transition
Pascal Behr, our co-founder and CEO for over a decade, has stepped down as CEO and remains on the Board of Directors. Simon Egli, our CCO for the past two years, has taken on the role of CEO. Read the Press Release
2024 - Start Collaboration with Altium International Inc. (US & Canada)
2024 - Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing
Read the Press Release and Download the Shared Application Note
2024 - Cytosurge’s CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
Read the Press Release and the Publication
2023 - First Post-Covid FluidFM Conference
2023 - First Live-seq OMNIUM customers: Institut Curie, FR, & EPFL, CH
2023 - Simon Egli appointed as Chief Commercial Officer, and Marin Gertsch as Chairman of the Board
2022 - Introduction of Live Cell Sequencing (Live-seq)
W. Chen, et al. Live-seq enables temporal transcriptomic recording of single cells. Nature 608, 733–740 (2022). https://doi.org/10.1038/s41586-022-05046-9
2022 - New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge
2021 - 30+ employees
2021 - Rebranding & New Website
2020 - One hundred FluidFM Installations Worldwide
2020 - Thomas Bachmann appointed to the Board of Directors
2020 - Improved & Enlarged Production Area
2020 - Partnership with Harvard’s Wyss Institute
Collaboration to investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity. Read the Press Release
2019 - Partnership with Olympus Europe
Read the Press Release
In 2020, also a partnership with Olympus America was concluded. Read the Press Release
2019 - First FluidFM Conference
More than 50 FluidFM users, researchers, and partners from around the globe gathered at ETH Hönggerberg in Zurich to showcase their results, gain insights, network, and profit from common solutions and approaches.
Read the Blog
2018 - Launch of the FluidFM BOT Platform
The FluidFM BOT was developed with the goal of having a highly automated solution for cell-based research that allows customers to miniaturize their established assays to the smallest possible element – the single cell itself.
2017 - Partnership with JPK Instruments
2013 - First Product for AFM launched with Nanosurf
2012 - ZKB Pionierpreis TECHNOPARK
2009 - Company Founded
Motivated by positive feedback and inquiries from peers in the scientific community, the two founders, Pascal Behr and Michael Gabi, decided that it was the right time to establish their own company.
2009 - First Publication on FluidFM
A. Meister & M. Gabi, et al. FluidFM: Combining atomic force microscopy and nanofluidics in a universal liquid delivery system for single cell applications and beyond. (2009) Nano Letters 9(6), 2501-2507. doi:10.1021/nl901384x
2006 - The Beginnings of FluidFM
Everything started with the idea of using force feedback to better control and guide the movements of a micro-/nanopipette.
Resources
Jobs
Join our team and make your contribution to promote FluidFM throughout the world!
Partners
We have partners in all major markets throughout Europe, Asia, and the Americas.
Contact us
Reach out to us about anything related to the FluidFM technology, to our company or services.
Blog
Interesting insights on the company, applications, or persons working with FluidFM technology.
Press Releases
Stay up to date with our news. Our media corner provides a convenient overview on all our press releases.